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Malariacontinuestobeamajorcauseofchildren’s morbidityandmortalityworldwide,causingnearlyonemilliondeathsannually.
The human malaria parasite, Plasmodium falciparum, synthesizes fatty acids employing the Type II fatty acid biosynthesis system
(FAS II), unlike humans that rely on the Type I (FAS I) pathway. The FAS II system elongates acyl fatty acid precursors of the
cell membrane in Plasmodium. Enoyl reductase (ENR) enzyme is a member of the FAS II system. Here we present steady-state
kinetics, pre-steady-state kinetics, and equilibrium ﬂuorescence spectroscopy data that allowed proposal of P. falciparum ENR
(PfENR) enzymemechanism.Moreover, building onprevious results, the present study alsoevaluates the PfENR inhibitionby the
pentacyano(isoniazid)ferrateIIcompound. This inorganiccomplex represents a new classof lead compounds for the development
of antimalarialagents focused on the inhibition of PfENR.
1.Introduction
Malaria, a disease caused by a protozoan pathogen of the
genus Plasmodium, remains one of the most devastating
human diseases, causing as many as 250 million new cases
and nearly one million deaths annually worldwide. This
disease is especially worrisome in Africa, where one out of
every ﬁve infant deaths is related to its eﬀects [1]. Although
malaria can be caused by mainly four species of the genus,
Plasmodium falciparum is responsible for the most severe
and deadly form of the disease and is to blame for 90% of
malaria-related deaths occurring in African children below
t h ea g eo fﬁ v e[ 2]. At present, the available drugs used
to ﬁght the disease are (a) aryl aminoalcohol compounds,
such as quinine [3], (b) antifolates-dihydrofolate reductase
inhibitors, such as pyrimethamine [4, 5], or (c) artemisinin
derivatives[6].Therapeutictreatment has, however,encoun-
tered serious obstacles, as this parasite has developed at
least partial resistance to nearly every antimalarial regimen
introducedtodate,includingtheﬁrst-line drugschloroquine
and sulfadoxine-pyrimethamine [7]. As single-drug treat-
ments are no longer adequate, combinations of two or more
drugs will probably oﬀer improved eﬃcacy and reduced
risk of emergence of drug-resistant parasites. Current exam-
ples of drug combinations are artemisinin-amodiaquine
and artemether-lumefantrine (Coartem) [8]. The lack of
an eﬀective prophylactic vaccine and the generation and
dissemination of drug-resistant strains clearly indicate the
needforthedevelopmentofnewtherapeuticapproachesand
identiﬁcation of novel targets.2 Enzyme Research
P. falciparum, a malarial parasite of the phylum Apicom-
plexa, has been found to contain an apicoplast, an organelle
that originally arose from a cyanobacterium through a sec-
ondary endosymbiotic process, and, thus, possesses four
membranes. During these endosymbiotic processes, resul-
tant of millions of years of adaptive selection, the endosym-
biont and host were integrated in a relationship involving
gene losses and gene transfers, resulting in a reduction of
the apicoplast genome to a bare minimum [9]. The majority
of the apicoplast proteins are encoded by genes in the
nuclear genome of the host, and the proteins that reside
in the apicoplast and are encoded by the nucleus are
posttranslationally targeted to the apicoplast organelle via
the secretory pathway, owing to the existence of a bipartite
N-terminal leader sequence [10]. In fact, the apicoplast is
indispensable for the malarial parasite, since several vital
metabolic processes for the parasite occur in this organelle.
Among these processes are isoprene, haem, and fatty acid
biosynthesis [11]. Fatty acid biosynthesis is critical for the
parasite development as fatty acids are the major compo-
nentsofcell membranes. Moreover, fatty acidsare important
source of energy, play a key role in signal transduction
as well as in protein acylation, and are needed for the
growth, diﬀerentiation, and homeostasis in P. falciparum.
It is also known that lipid biosynthesis is highly increased
during the erythrocytic phases, when the parasite grows
and divides extremely fast [12]. As the parasite invades its
host, it attempts to protect itself by creating a so-called
parasitophorous vacuole, in part as a protection from the
host’simmunesystem[13].Inthisprocess,theparasiteneeds
to produce its own fatty acids de novo so as to form and
expand its membrane [14].
The enzymes involved in the biosynthesis of fatty
acids are organized in two distinct ways within living
systems. Fungi, mammals, and some mycobacteria accom-
plish fatty acid synthesis through the action of multifunc-
tional proteins, each reaction being catalysed by a distinct
region (domain) of these single-polypeptide proteins. These
enzymes are classiﬁed as Type I fatty acid synthases (FAS
I) and are also described as the “associative” type of fatty
acid synthases, as successive steps in the fatty acid synthetic
reaction occur at speciﬁc domains [15, 16]. In contrast,
plants and many bacteria use the Type II or “dissociated”
fatty acid synthases (FAS II), whose enzymes are best
characterized in Escherichia coli [17]. Each step of the FAS
II system is catalysed by a speciﬁc enzyme encoded by a
separate gene. Since the FAS II is absent in humans, it
represents a great opportunity for therapeutic applications.
The fatty acid chain elongation module of FAS II consists
of the cycling of the growing fatty acyl moiety through
four key enzymes. Elongation is initiated by β-ketoacyl-
ACP synthase I/II (FabB/FabF) enzyme, which catalyses the
condensation of the growing fatty acyl ACP with malonyl-
ACP to yield a β-ketoacyl-ACP with an additional two-
carbon unit. The second step is the reduction of β-ketoacyl-
ACP to β-hydroxyacyl-ACP catalysed by the β-ketoacyl-
ACP reductase (FabG) enzyme. Water is then removed
by β-hydroxydecanoyl-ACP dehydratase/isomerase (FabA)
and/or β-hydroxyacyl-ACP dehydratase (FabZ) to produce
2-trans-enoyl-ACP. The ﬁnal step in the elongation process
is the NADH-dependent reduction of the double bond to
produce fatty acyl ACP, which is catalysed by FabI, the
only enoyl-ACP reductase (ENR) enzyme in Plasmodium
(Figure 1). Successive elongation cycles typically lead to the
formation of decanoic (C-10), lauric (C-12), and myristic
(C-14)acidsasthemajorfattyacylA CP sinPlasmodium[13],
whereas palmitic (C-16) acid is the most predominant fatty
acid synthesized in humans [12].
ENR from Mycobacterium tuberculosis (MtInhA) was
ﬁrst identiﬁed as being the primary target for isoniazid
(INH; Figure 2(a))[ 18], the most prescribed drug to treat
active tuberculosis. The enzyme is an NADH-dependent
enoyl-ACP reductase speciﬁc for long-chain enoyl thioester
substrates. MtInhA is a member of the mycobacterial FAS
II, which elongates acyl fatty acid precursors of mycolic
a c i d s .I N Hi sap r o d r u gt h a ti sa c t i v a t e db yt h ed e
mycobacterial katG-encoded catalase-peroxidase enzyme in
the presence of manganese ions, NAD (H) and oxygen
[19, 20]. Approximately 50% of M. tuberculosis INH-
resistant clinical isolates harbor deletions of, or missense
mutations in, the katG gene [21, 22]. The KatG-produced
acytylpyridine fragment of INH is covalently attached to
the C4 position of NADH and forms a binary complex
with the wild-type MtInhA [23]. This isonicotinoyl-NAD+
adduct has been characterized spectroscopically and shown
to bind to the enzyme with a dissociation constant value
lower than 0.4nM [24]. The isonicotinoyl-NAD+ adduct has
been shown to be a slow, tight-binding competitive inhibitor
of wild-type MtInhA [25]. The initial rapidly reversible weak
binding (Ki = 16nM) is followed by a slow isomerization,
leadingtoatighterenzyme-inhibitorcomplexwithanoverall
dissociation constant (K
∗
i ) value of 0.75nM.
The mechanism of action of INH requires its conversion,
by the mycobacterial KatG, into a number of electrophilic
intermediates [20]. The formation of the adduct has been
proposed to be formed through the addition of either
an isonicotinic acyl anion to NAD+ or an isonicotinic
a c y lr a d i c a lt oa nN A Df r e er a d i c a l[ 23]. The peroxidase
activity of KatG catalyses the conversion of Mn2+ to Mn3+
[26]. Rapid freeze-quench electron paramagnetic resonance
spectroscopy experiments have shown that hydrogen atom
abstractions may be initiated by a KatG tyrosil radical
[27]. Furthermore, it has been shown that the yield of
isonicotinoyl-NAD+ adductisaboutthesame afteroxidation
of INH by KatG or Mn3+ [28]. Accordingly, oxidation by
Mn3+-pyrophosphate has been proposed as an alternative
method for nonenzymatic INH activation for simple chem-
ical synthesis of various INH derivatives that mimic the
isonicotinoyl-NAD+ adduct [29]. Based on the activation
mechanism proposed for INH, via an electron transfer
reaction, an alternative self-activation inner-sphere electron
transfer reaction route was proposed for designing new
drugs for the treatment of INH-resistant and INH-sensitive
tuberculosis. These drugs would be activated by electron
transfer reactions before interacting with their cellular tar-
gets,and a redoxreversiblemetal complexcoordinatedtothe
prodrug was employed as a prototype. Accordingly, we have
recentlydemonstratedthatpentacyano(isoniazid)ferrateIIorEnzyme Research 3
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Figure 1: Reaction catalysed by PfENR.
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[FeII(CN)5(INH)]3− (Figure 2(b)) inhibits the activity of
both wild-type and I21V mutant (INH-resistant) MtInhA
enzymes [30]. The in vitro kinetics of inactivation indicates
that this process requires no activation by KatG, no need for
the presence of NADH, and is also eﬀective against INH-
resistant InhA mutants. An MIC value of 0.2μgmL −1 for
this inorganic complex was determined by the radiometric
BACTEC AFB system for the M. tuberculosis H37Rv strain,
and toxicity assays in HL60 leukemia and MCS-7 breast
cancer cells yielded an IC50 value greater than 25μgmL −1,
thereby indicating a good selectivity index (SI = IC50/MIC
> 125; the Tuberculosis Antimicrobial Acquisition and
Coordinating Facility of USA suggests that in order to a
compound move forward through screening programs, SI
should be larger than 10). More recently, we have shown that
the [FeII(CN)5(INH)]3− complex is a slow-onset inhibitor
of MtInhA enzyme activity, with a true overall dissociation
constant value of 70nM [31]. In this mechanism of action
an initial enzyme-inhibitor complex is rapidly formed,
which then undergoes a slow isomerization reaction of an
enzyme-inhibitor binary complex, where the inhibitor is
more tightly bound to enzymes. The weakness in the use of
classical enzyme inhibitors as drugs for clinical conditions
is that inhibition results in the upstream accumulation of
the substrate for the enzyme, which may overcome the
inhibition. By contrast, the build-up of substrate cannot
have any eﬀect on the isomerization of the enzyme-inhibitor
complex typical of the slow-onset mechanism and hence
reversal of the inhibition [32].
The structural similarity between MtInhA and PfENR
stimulated us to test the [FeII(CN)5(INH)]3− against the
malarial enzyme. This work investigates the eﬃcacy of the
[FeII(CN)5(INH)]3− compound against PfENR. In addition,
we propose an enzyme mechanism for PfENR based on
steady-state kinetics, pre-steady-state kinetics, and ﬂuores-
cence spectroscopy data.
2.Materialsand Methods
2.1. Materials. All chemicals used were of analytical
or reagent grade and required no further puriﬁcation.
Crotonoyl-CoA, NADH, and butyryl-CoA were from Sigma
(Steinheim, Germany). PfENR (EC 1.3.1.9) was expressed
and puriﬁed by Genscript Corp., New Jersey, USA. The
[FeII(CN)5(INH)]3− compound was a kind gift of Dr. Luiz
G.F Lopes and Dr. Eduardo H.S. Sousa from Universidade
Federal do Cear´ a, Departamento de Qu´ ımica Orgˆ anica e
Inorgˆ anica, Fortaleza, CE, Brazil. The steady-state activity
assays were carried out in a UV-2550 UV-Visible Spec-
trophotometer, and ﬂuorescence binding experiments were
carried out in an RF-5301PC Spectrophotometer, both from
Shimadzu (Kyoto, Japan).
All enzyme activity assays were performed under initial
rate conditions at 25◦C in 100mM sodium phosphate
buﬀer pH 7.5 in 500μL total reaction volumes, and each
individual initial rate datum was the average of duplicate or
triplicate measurements. Crotonoyl-CoA, NADH, butyryl-
CoA, [FeII(CN)5(INH)]3−, and the enzyme were dissolved
in 100mM sodium phosphate buﬀer pH 7.5. The reactions
were monitored by the decrease in absorbance at 340nm
due to the conversion of NADH (ε340 = 6220M−1 cm−1)t o
NAD+.
2.2. Initial Velocity. In order to determine the true steady-
state kinetic parameters and initial velocity patterns, PfENR
activity was measured in the presence of varying concen-
trations of crotonoyl-CoA (10–240μM) and several ﬁxed-
varied NADH concentrations (20–200μM), and reactions
were initiated by the addition of 0.12μMo fP f E N Ri n t ot h e
reaction mixture.4 Enzyme Research
2.3. Fluorescence Spectroscopy. Fluorescence titration was
performed to assess the dissociation constant at equilib-
rium for binary complexes formed between PfENR and
either substrate(s) or product(s) at 25◦C. Crotonoyl-CoA,
NADH, butyryl-CoA, and PfENR were dissolved in 100mM
sodium phosphate buﬀer pH 7.5. Fluorescence titration
with crotonoyl-CoA was carried out by making micro-
liter additions of 0.5mM and 5mM crotonoyl-CoA stock
solutions (0.50–425.97μM crotonoyl-CoA ﬁnal concentra-
tions) to 1mL of 3μM PfENR, keeping the dilution to a
maximum of 10.1%. Measurements of changes in intrinsic
protein ﬂuorescence of PfENR upon crotonoyl-CoA binding
employed excitation wavelength at 305nm, and the emission
wavelengths ranged from 325 to 370nm (maximum PfENR
λEM = 348nm); the slits for excitation and emission
wavelengths were, respectively, 15 and 5nm. Fluorescence
titration with NADH was carried out by making micro-
liter additions of 0.5mM, 1mM, and 5mM NADH stock
solutions (0.50–119.21μM NADH ﬁnal concentrations) to
1mL of3μM PfENR, keeping the dilution to a maximum
of 4.1%. Measurements of changes in NADH ﬂuorescence
upon binding to PfENR employed excitation wavelength at
360nm, and the emission wavelengths ranged from 360 to
560nm (maximum λEM = 460nm); the slits for excitation
and emission wavelengths were, respectively, 1.5 and 5nm.
Fluorescence titration with butyryl-CoA was carried out
by making microliter additions of 0.5mM, 2.5mM, 5mM,
and 10mM butyryl-CoA stock solutions (0.50–550.85μM
butyryl-CoA ﬁnal concentrations) to 1mL of 3μMP f E N R ,
keeping the dilution to a maximum of 8.4%. Measurements
of changes in intrinsic protein ﬂuorescence upon butyryl-
CoA binding to PfENR employed excitation wavelength at
300nm, and the emission wavelengths ranged from 320 to
400nm (maximum PfENR λEM = 337nm); the slits for
excitation and emission wavelengths were, respectively, 5
and 10nm. Control experiments were employed to both
determine the maximum ligand concentrations to be used
with no inner ﬁlter eﬀect and determine dilution eﬀects on
protein ﬂuorescence. No ﬂuorescence titration with NAD+
could be performed due to a large inner ﬁlter on protein
ﬂuorescence.
2.4. Pre-Steady-State Kinetics. Pre-steady-state kinetic mea-
surements of NADH→NAD+ conversion by PfENR were
carried out to conﬁrm the proposed kinetic mechanism
and assess whether the apparent rate constant for this
conversioncontributestotherate-limiting step.Thedecrease
in absorbance upon NADH conversion to NAD+ was moni-
tored at 340nm (1mm slit width = 4.65nm spectral band),
at 25◦C, using a split time base (0.2–2s; 200 data points for
each time base). The experimental conditions were 3.14μM
PfENR and 200μM NADH in 100mM sodium phosphate
buﬀer pH 7.5 (mixing chamber concentrations). The dead
time of the stopped-ﬂow equipment is 1.37ms.
2.5. [FeII(CN)5(INH)]3− In Vitro Activity against PfENR.
[FeII(CN)5(INH)]3− time-dependent inhibition of PfENR
was performed since it had been observed in MtInhA [31].
The enzyme was preincubated with the inhibitor for 15min
(2.77:2455μM enzyme:inhibitor solution), and the activity
was monitored by adding 0.12:54μMe n z y m e : i n h i b i t o r
mixture aliquots, with diﬀerent times of exposure, to
the reaction mixtures which contained crotonoyl-CoA and
NADH concentrations close to their KM values. The reaction
was monitored by following enzyme activity during the time
course.
2.6.Slow-Binding Inhibition Kinetics of PfENR by[FeII(CN)5·
(INH)]3−. Typical slow-binding experiments were carried
out in the presence of various [FeII(CN)5(INH)]3− concen-
trations as an attempt to elucidate the kinetic mechanism
of the time-dependent inhibition observed for PfENR. In
the case of slow-binding inhibitors, the binding, which is
comprised by the establishment of the equilibrium between
enzyme, inhibitor, and enzyme-inhibitor complexes, occurs
slowly in a time scale of seconds to minutes [32]. These
experiments were conducted under conditions in which
[FeII(CN)5(INH)]3− concentrations were signiﬁcantly larger
than enzyme concentration, and measurements were made
within a time range over which there was no signif-
icant substrate depletion. The assay mixtures contained
80μMcrotonoyl-CoA,120μMNADH,2%(vol/vol)glycerol,
49.7μgmL −1 BSA, and 0–35μM[ F e II(CN)5(INH)]3−.T h e
reactions were initiated by adding enzyme (0.69nM) to the
assay mixture and were monitored by following the decrease
in NADH absorbance at 340nm for 21600s (6 hours).
Enzyme activity was stabilized by the addition of glycerol
and BSA to the reaction mixture as described for MtInhA
[25, 31].
2.7. Two-Step Mechanism of PfENR Inhibition by [FeII(CN)5·
(INH)]3−. The two-step mechanism observed for MtInhA
inhibition by [FeII(CN)5(INH)]3− [31] was investigated
for PfENR. The latter was preincubated in the presence
of various concentrations of [FeII(CN)5(INH)]3−,a n dt h e
decrease of PfENR activity was assessed by withdrawing
aliquots from the preincubation mixtures at appropriate
intervals, followed by rapid measurement of initial velocity.
Reactions of time-dependent inactivation of PfENR were
carried out in mixtures containing 12μMP f E N Ra n d
various concentrations of inhibitor. Control experiments
were performed with no inhibitor. At various times, the
residual enzyme activity was determined by diluting an
aliquot (100-fold) of the reaction mixture into the assay
solution, which contained 40μMc r o t o n o y l - C o Aa n d5 0μM
NADH.
2.8. Data Analysis. The kinetic parameter values and their
respective standard errorswere obtainedbyﬁttingthedatato
the appropriate equations by using the nonlinear regression
function of SigmaPlot 2004 (SPSS, Inc.).
Apparently parallel family of lines of initial velocity
data were tentatively ﬁtted to (1), which describes a double
displacement mechanism [33]. For (1), v is the measured
reaction velocity, V is the maximal velocity, A and B areEnzyme Research 5
the concentrations of the substrates (NADH and crotonoyl-
CoA),and Ka andKb aretheirrespectiveMichaelis constants:
v =
VAB
KaB +KbA +AB
. (1)
Data from equilibrium ﬂuorescence spectroscopy were
ﬁtted either to a hyperbolic function ((2); [34]) or to the
Hill equation ((3); [35]). For (2)a n d( 3), F is the observed
ﬂuorescence signal, Fmax is the maximal ﬂuorescence, F/Fmax
ratio represents the degree of saturation, A is the concen-
tration of the ligand (either NADH or butyryl-CoA), n
represents the total number of binding sites, Kd is the overall
dissociation constant, and K  represents a mean dissociation
constant for enzyme: ligand binary complex formation,
which is comprised of interaction factors and the intrinsic
dissociation constant [36, 37]:
F
Fmax
=
A
Kd + A
,( 2 )
F
Fmax
=
An
K  +An. (3)
The equilibrium ﬂuorescence data representing the frac-
tional saturation (0.10–0.90) for the homotetrameric form
[38]o fP f E N Rw e r eﬁ t t e dt o( 4) (the Hill plot), in which
Y is the fraction of substrate binding sites occupied by the
substrate and h is the Hill coeﬃcient:
log

Y
1 − Y

= hlogA − logK . (4)
T h ep r e - s t e a d y - s t a t et i m ec o u r s eo fN A D H →NAD+
conversion was ﬁtted to (5) for a single exponential decay,
in which A is the absorbance at time t, A0 is the absorbance
at time zero, and k is the apparent ﬁrst-order rate constant
for product formation:
A = A0e
−kt. (5)
Apparent pseudoﬁrst-order rate constants were calcu-
lated by ﬁtting the progress curves for time-dependent
inactivation of PfENR to integrated equation (5)f o rs l o w -
binding inhibition [25, 32, 39]. For (6), At and A0 are the
340-nm absorbances at time t and time 0, v0, vs,a n dkobs
represent, respectively, the initial velocity, the ﬁnal steady-
state velocity, and the apparent ﬁrst-order rate constant for
the establishment of the equilibrium between EI and EI∗
complexes (the observed rate constant for formation of EI∗
or the apparent isomerization rate constant):
At = vst +
(v0 − vs)

1 − e−kobst

kobs
. (6)
An estimate of the apparent dissociation constant (K
app
i )
was obtained by ﬁtting the variation of initial rate (v0)w i t h
inhibitor concentration (I)t o( 7) for competitive inhibition,
in which v0max is the initial velocity in the absence of
inhibitor [31]:
v0 =
v0max
1+[I]/K
app
i
. (7)
A “true” value for the apparent dissociation constant Ki
for the initial enzyme-inhibitor binary complex (EI) can be
calculated by (8), in which KNADH and KCrotonoyl-CoA are the
values for the Michaelis-Menten constants and [NADH]and
[Crotonoyl-CoA] are the concentration values used in the
slow-onset inhibition assays:
Ki =
K
app
i
1+[NADH]/KNADH+

Crotonoyl-CoA

/KCrotonoyl-CoA
.
(8)
The data from two-step mechanism studies of PfENR
inhibition by [FeII(CN)5(INH)]3− were ﬁtted to (9), in
which Ki is the dissociation constant for the initial enzyme-
inhibitor binary complex (EI), k5 is the forward isomeriza-
tionrateconstantforconversionofEItoEI∗,k6 isthereverse
isomerization rate constant (conversion ofEI∗ to EI), I is the
concentration of inhibitor ([FeII(CN)5(INH)]3−), and kinact
is the apparent ﬁrst-order constant for enzyme inhibition:
kinact = k6 +
k5I
Ki + I
. (9)
3.Resultsand Discussion
3.1. Initial Velocity Patterns and Kinetic Constants. Initial
velocity patterns were determined using either crotonoyl-
CoA or NADH as the variable substrate to distinguish
between a sequential and a double displacement (“ping-
pong”) mechanism, providing information regarding the
order of substrate binding. Double-reciprocal plot [40]
analysis revealed a parallel line pattern for both substrates
(Figure 3), which is consistent with a double displacement
mechanism. In this mechanism, a catalytic event can occur
when only one of the two substrates is bound to the enzyme.
AcatalyticeventoccursafterthebindingofsubstrateAtothe
enzyme (E), but prior to the binding of substrate B. After the
ﬁrst catalytic event, a portion of substrate A remains in the
active site of the enzyme, whereas the other portion denoted
as product P dissociates. The ﬁrst catalytic event produces
ad i ﬀerent stable enzyme form (F) to which substrate B
can bind and proceed with catalysis to generate product Q
and regenerate free enzyme (E). The data were tentatively
ﬁtted to (1), yielding the following values for the true
steady-state kinetic constants: Vmax = 5.8( ±0.3)Umg−1,
kcat = 6.2( ±0.4)s−1, KNADH = 85 (±9)μM, KCrotonoyl-CoA =
63 (±6)μM, kcat/KNADH = 7.3( ±0.9) × 104 M−1 s−1,a n d
kcat/KCrotonoyl-CoA = 9.8( ±1.1) × 104 M−1 s−1.
There are, however, some conditions where lines that
seem parallel really are not. For an Ordered Bi Bi system in
which the dissociation constant for substrate A (Kia)i sv e r y
much smaller than the Michaelis-Menten constant for A (Ka
or KMA), the family of reciprocal plots intersect far to the left
of the 1/v axis and far below the 1/[A] axis [36]. In addition,
seemingly parallel initial velocity patterns can also occur in
rapid equilibrium random systems where the binding of one
substrate strongly inhibits the binding of the other.
3.2. Equilibrium Binding of Ligands to PfENR. Equilibrium
binary complex formation experiments were employed to6 Enzyme Research
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NADH (a) or crotonoyl-CoA (b) as the variable substrate. Each
curve represents varied-ﬁxed levels of the cosubstrate: one unit
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conﬁrm, or refute, the proposed enzyme mechanism. There
was anenhancement innucleotideﬂuorescenceuponNADH
binding to PfENR, whereas butyryl-CoA binding to PfENR
resulted in intrinsic protein ﬂuorescence quench. Titration
of PfENR with NADH was hyperbolic (Figure 4(a)), and the
data were ﬁtted to (3) yielding a value of 398 (±53)μMf o r
the overall dissociation constant (Kd)o fN A D H .E n z y m e
titration with butyryl-CoA was sigmoidal (Figure 4(b)), and
the data were best ﬁtted to (4) yielding a value for K  for
butyryl-CoA of 1151 (±638)μM. The value for K  repre-
sents a mean dissociation constant for PfENR:butyryl-CoA
binarycomplexformation, whichiscomprisedofinteraction
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Figure 4: Overall dissociation constant for PfENR: NADH (a) and
PfENR:butyryl-CoA (b) binary complex formation monitoring
changes in, respectively, nucleotide and intrinsic protein ﬂuores-
cence. (c) Hill logarithmic plot of the data between 10% and 90%
active site saturation with butyryl-CoA. Inset represents the ﬁt of
double-reciprocal plot of the ﬂuorescence data to an exponential
growth equation.Enzyme Research 7
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Figure 5: Representative stopped-ﬂow trace for NADH→NAD+
conversion. Fitting the exponential decay data to (5)y i e l d e da
value of 1100 (±29)s−1 for the apparent ﬁrst-order rate constant
ofproduct formation.The top trace represents the chemicalcontrol
(200μM NADH), and the single exponential decay represents the
reaction upon mixing 3.14μM PfENR and 200μMN A D H( m i x i n g
chamber concentrations).
factors and the intrinsic dissociation constant [36, 37]. A
Hill plot of the data (Figure 4(c))ﬁ t t e dt o( 4)y i e l d e da
value larger than one for h (1.6 ± 0.1). The latter indicates
moderatepositivehomotropiccooperativityonbutyryl-CoA
binding to tetrameric PfENR, which is further supported
by the upward-curved double-reciprocal plot (Figure 4(c)—
inset). No intrinsic protein ﬂuorescence change upon
addition of crotonoyl-CoA to PfENR could be observed,
suggesting that this compound cannot bind to free PfENR
enzyme. Protein ﬂuorescence titration with NAD+ could not
be performed due to large inner ﬁlter eﬀect.
3.3. Pre-Steady-State Kinetics. Steady-state kinetics data sug-
gested that PfENR follows a double displacement (“ping-
pong”) mechanism. Fluorescence spectroscopy data showed
that NADH binds to free enzyme whereas it appears that
crotonoyl-CoA cannot. Although butyryl-CoA binding to
free enzyme resulted in protein ﬂuorescence quench, it is
not certain whether crotonoyl-CoA cannot bind to free
enzyme or its binding results in no change in protein
ﬂuorescence. Hence, the Ordered Bi Bi and rapid equi-
librium random mechanisms could not be ruled out. To
try to address this uncertainty, pre-steady-state kinetics
measurements were carried out to show whether or not
there is hydride transfer in the absence of crotonoyl-CoA
as expected for the double displacement mechanism with
NADH binding ﬁrst. Moreover, determination of a value
for the apparent ﬁrst-order rate constant for the course of
NADH→NAD+ conversion could also indicate whether or
not this step is rate limiting. It should be pointed out that
NADH concentration was in excess as compared to PfENR
concentration, so that any burst in product formation could
be reliably assessed [41, 42]. Fitting the pre-steady-state
trace showing a single exponential decay upon NADH→
NAD+ conversion (Figure 5)t o( 5) yielded a value of 1100
(±29)s−1 for the apparent ﬁrst-order rate constant for
product formation (1cm pathlength). The NADH→NAD+
conversion step has thus no contribution to rate-limiting
step(s) as its value is much larger than the catalytic rate
constant value. There was an apparent accumulation of
observable product (NAD+)o nt h ee n z y m ea c t i v es i t e s
when high concentration of PfENR (3.14μM) was mixed
with NADH (200μM). Taken together, steady-state kinetics,
pre-steady-state kinetics, and equilibrium binding data are
consistentwithadoubledisplacementmechanismforPfENR
(Figure 6). In this mechanism, a catalytic event occurs
after the binding of NADH to free enzyme (E), generating
and releasing NAD+ into solution prior to the binding
of crotonoyl-CoA to a modiﬁed form of the enzyme (F),
followed by formation of butyryl-CoA and regeneration of
free enzyme(E)(Figure 6).The enzymemechanism hasbeen
shown to be ordered sequential with enoyl-ACP substrate
binding ﬁrst for Staphylococcus aureus enoyl reductase [43]
and ordered sequential with NADH binding ﬁrst for fabV-
encoded enoyl reductase from Burkholderia mallei [44].
Although uncommon for reductases/dehydrogenases, dou-
ble displacement mechanisms have been described for Enter-
obacter cloacae nitroreductase [45], Salmonella typhimurium
histidinol dehydrogenase [46], bovine liver mitochondrial
dihydroorotate dehydrogenase [47], and mammalian pyru-
vate dehydrogenase complex [48]. Of course, no mecha-
nism is ever proved; at best one can say that given the
current data the likely mechanism for PfENR is double
displacement. Further eﬀorts are needed to provide support
for either the double displacement mechanism or any
other that may give a better description of the experimental
results.
Based on substrate binding to immobilized PfENR by
Surface Plasmon Resonance (SPR) results, it has been
proposedthatPfENRenzymemechanism israndomorderof
substrate addition [49]. Althoughthere have beenreports on
determination of apparent steady-state kinetics parameters
for PfENR [38, 50, 51], to the best of our knowledge,
no data have been presented for determination of true
steady-state kinetic parameters on which to base a proposal
for PfENR enzyme mechanism in solution. To determine
the true steady-state kinetic parameters and initial velocity
patterns for distinguishing mechanisms, enzyme activity
measurements have to be carried out in the presence of
varying concentrations of one substrate and several ﬁxed-
varied concentrations of the other substrate. Interestingly,
the Kd value of 398μM for NADH is approximately 8-fold
larger than a previously reported value (51.6μM) by SPR
[49]. These results are somewhat puzzling as equilibrium
constants determined by SPR usually match well the values
obtained by solution techniques (ﬂuorescence spectroscopy,
isothermal titration calorimetry). In addition, a Kd value
of 62.5μM for crotonoyl-CoA has been determined by SPR
measurements [49], whereas no change in intrinsic PfENR
protein ﬂuorescence could be detected upon addition of
crotonoyl-CoA to free enzyme. Incidentally, the true steady-
state value for kcat (6.2s−1) reported here is approximately8 Enzyme Research
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Figure 6: Proposed mechanism for the PfENR-catalysed chemical reaction.
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Figure 7: Time-dependent inactivation of PfENR by 0–35μM
[FeII(CN)5(INH)]3−. The solid curves represent the best ﬁt of the
data to (5) for slow-binding inhibition. The assay mixtures were
kept at 25◦C and contained 100mM sodium phosphate buﬀer pH
7.5, 80μM crotonoyl-CoA, 120μM NADH, 2% (vol/vol) glycerol,
49.7μgmL −1 BSA,and0–35μM[F e II(CN)5(INH)]3−.Thereactions
were initiated by the addition of enzyme (0.69nM) to the assay
mixture and were monitored by following the decrease in NADH
absorbance at 340nm for 21600s (6 hours).
4-fold larger as compared to an apparent value (1.62s−1)
described elsewhere [51].
3.4. Slow-Onset Inhibition Kinetics of PfENR by [FeII(CN)5·
(INH)]3−. We have previously shown that [FeII(CN)5·
(INH)]3− compound (Figure 2(b))i sas l o w - o n s e ti n h i b i t o r
of wild-type and drug-resistant MtInhAs [30, 31, 52].
We then anticipated that [FeII(CN)5(INH)]3− may also be
an eﬀective inhibitor of PfENR enzyme activity. Prior to
embarking on a full analysis of the mode of inhibition
o fP f E N Ra c t i v i t yb y[ F e II(CN)5(INH)]3− compound, the
enzyme was preincubated with inhibitor, and aliquots were
withdrawn at diﬀerent times to measure the remaining
residual activity. PfENR inhibition by [FeII(CN)5(INH)]3−
was time dependent (data not shown). Thereby, PfENR
slow-binding experiments were carried out in the presence
of various concentrations of [FeII(CN)5(INH)]3− to try to
elucidate the mechanism of the observed time-dependent
enzyme inhibition. The progress curves for enzyme activity
indicate that [FeII(CN)5(INH)]3− is a slow-onset inhibitorof
PfENR (Figure 7).
Three basic slow-onset inhibition mechanisms have
been described by Morrison and Walsh (Figure 8;[ 32]).
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Figure 8:Mechanismsthatdescribe reversible slow-bindinginhibi-
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Figure 9: Two-step inactivation of PfENR by [FeII(CN)5(INH)]3−.
The values for the apparent ﬁrst-order rate constant of inactivation
(kinact) were obtained from a plot of residual enzyme activity
versus time (not shown). The kinact values were plotted against
[FeII(CN)5(INH)]3− concentration in the preincubation mixture.
T h ed a t aw e r eﬁ t t e dt o( 6).Enzyme Research 9
In mechanism A (Figure 8), it is assumed that the time-
dependent enzyme inactivation observed is resultant of a
slow bimolecular enzyme-inhibitor interaction, because the
inhibitor concentration is low and/or due to barriers that
the inhibitor encounters in its binding at the enzyme’s active
site. In mechanism B (Figure 8), it is assumed that there
is an initial rapid enzyme-inhibitor interaction to form EI,
which then undergoes a slow isomerization (conformational
change) to EI∗ [53]. For inhibitors that conform to this
mechanism, the overall dissociation constant (K∗
i )m u s tb e
lower than the dissociation constant for initially formed
complex EI (Ki), a condition that can be satisﬁed only when
k6 <k 5 (K∗
i = Kik6/(k5 + k6)a n dw h e nk5 and k6 are
slower than all other steps [32]. According to mechanism
B ,i nt h ep r e s e n c eo faﬁ x e dc o n c e n t r a t i o no fs u b s t r a t e
(A), the value of kobs increases hyperbolically as a function
of inhibitor concentration with limiting values of k6 and
k5 + k6 at, respectively, zero and inﬁnite concentrations of
inhibitor. As described in Section 2, kobs in (6)r e p r e s e n t st h e
apparent ﬁrst-order rate constant for the establishment of
theequilibriumbetween EIand EI∗ complexes(the observed
rateconstantforformation ofEI∗ ortheapparentisomeriza-
tion rate constant). A third mechanism (mechanism C) has
also been described to account for slow-binding inhibition
of enzyme-catalysed reactions (Figure 8). This mechanism
involves a slow initial isomerization of two forms of free
enzyme in solution (E and E∗), followed by a rapid binding
of inhibitor to form E∗Ic o m p l e x .T h ekf and kr stand,
respectively,fortheforward andreverserateconstantsforthe
conversion of free enzyme (E) to a form of free enzyme (E∗)
to which the inhibitor binds. However, ﬁtting the kobs values
as a function of [FeII(CN)5(INH)]3− inhibitor concentration
yielded a plot that did not allow to draw solid conclusions
on the mechanism. On the other hand, ﬁtting the initial rate
values (v0) as a function of [FeII(CN)5(INH)]3− inhibitor
concentration to (7) yielded a value of 40 (±11)μMf o r
K
app
i .A“ t r u e ”v a l u eo f1 1( ±3)μM for the apparent
dissociation constant Ki for the initial enzyme-inhibitor
binary complex (EI) could thus be calculated by employing
(8).
3.5. Two-Step Mechanism of PfENR Inhibition by [FeII(CN)5·
(INH)]3−. The two-step mechanism of PfENR inhibition by
[FeII(CN)5(INH)]3− was assessed by an experiment in which
the enzyme was preincubated in the presence of various con-
centrations of inhibitor and the decrease of PfENR activity
was assessed by withdrawing aliquots of enzyme from prein-
cubationmixtures atappropriateintervals, followed by rapid
measurement of initial velocity. These results were analyzed
in terms of a two-step inhibition mechanism in which the
initial rapidbindingoftheinhibitor toenzyme isfollowed by
a second slow step that results in the ﬁnal enzyme-inhibitor
complex. Since the value of Ki is much larger than K∗
i ,
the inhibitor concentration in the assay solution is lower
than the Ki value ([I] <K i), and there is a large excess
of the competitive substrates NADH and crotonoyl-CoA
over [FeII(CN)5(INH)]3−, the steady-state concentration of
EI in the assay solution is kinetically insigniﬁcant [31].
The apparent ﬁrst-order rate constants for PfENR inac-
tivation (kinact) could be calculated from a plot of re-
sidual enzyme activity against time for each inhibitor
concentration. A plot of kinact values versus inhibitor con-
centration shows that the kinact valuesincrease hyperbolically
as a function of inhibitor concentration (Figure 9), which
is consistent with mechanism B (Figure 8). These data
were thus ﬁtted to (9), which describes the slow-binding
inhibition for mechanism B, yielding values of 58 (±12)μM
for Ki,5 3( ±2)s−1 for k5,a n d4( ±2)s−1 for k6.Av a l u e
of 4μM can thus be calculated for the overall inhibition
constant (K
∗
i = Kik6/(k5 + k6). It should be pointed out that
an independent estimate for the K∗
i value could be obtained
by plotting the ﬁnal steady-state velocity (vs)a saf u n c t i o n
of [FeII(CN)5(INH)]3− inhibitor concentration and ﬁtting
the data to (7) for competitive inhibition. However, the data
were notconsistentastheexperimentaldataappeartodepart
somewhat from the values predicted by ﬁtting the data to
(6).
The two-step mechanism followed by [FeII(CN)5·
(INH)]3− inactivation of PfENR involves an enzyme-inhib-
itor isomerization step. The enzyme isomerization could
involve, for instance, a protein conformational change or
alteration of water structure at the active site. For the
inhibitor, the change could be hydration/dehydration of a
carbonyl, change in ionization state, or a conformational
change. These alterations could take place in the enzyme-
inhibitor complex or in solution [54].
4.ConcludingRemarks
T h ew e a k n e s si nt h eu s eo fc l a s s i c a le n z y m ei n h i b i t o r s
as drugs for clinical conditions is that inhibition results
in the upstream accumulation of the substrate for the
enzyme, which may overcome the inhibition. By contrast,
the build-up of substrate cannot have any eﬀect on the
isomerization of enzyme-inhibitor complex typical of the
slow-onset mechanism and hence reversal of the inhibition
[32]. Moreover, the low half-time value for the limiting
step for inhibitor dissociation from the binary complex is
a desirable feature since it may be expected to enhance
inhibitor’s eﬀectiveness [54]. It has recently been proposed
by scientists at GlaxoSmithKline (USA) that measurement
of the dissociative half-life is a crucial metric of compound
optimization and could be a keyindicatorof in vivo duration
of eﬃcacy and target selectivity [55]. It has recently been
shown that [FeII(CN)5(INH)]3− compound has a promising
proﬁle in toxicological assays and that it is amenable to
large-scale production [56]. These features indicate that
[FeII(CN)5(INH)]3− compound is a viable candidate for
further studies (including in vivo eﬃcacy) and that it may
represent a prototype for the development of chemothera-
peutic agents to treat malaria.
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